Vascular Biology
Monterey, CA
Lymphatic Forum 2019
Austin, TX
May 30 - June 1, 2019
Vasculata 2019
Medical College of Wisconsin
July 13 - 18, 2019
|
UT Southwestern
Medical Center
|
|
Partner Network Advantage - New Job Board Feature
|
Why post your job on NAVBO's career center rather than going directly to the larger job networks?
Pricing on the mass job boards can vary, but to get a job noticed you typically have to sponsor it for $5 - $10 per day, which can add up quickly especially since you also pay for each click the job gets. When you add it all together, you could be spending up to $45 per day on your job posting. But, when posting a job on NAVBO's career center, you simply pay a flat fee! The Premium package includes our Exclusive Extended Partner Network - which means the jobs are broadcast to sites like ZipRecruiter and Jobs2Careers and more for a flat fee.
With special member pricing, you can post a job for as low as $300 with this Partner Network. You never pay for each click, just the flat fee on the NAVBO career center. In addition, the Premium package includes a 60-day job posting making it a great value. The Premium packages also offer features like having your company's logo featured on the career center homepage, having your job appear first in search results, and more.
|
Shop at Amazon?
Help Support NAVBO
|
Your data privacy and security are important to NAVBO. To that end, we have updated our privacy policy to reflect recent privacy and security regulation implementations and changes.
Please review our policy as time permits so you have a complete understanding of the data we have, why we have it, and how we use it.
Part of the updates relate directly to the European Union's new General Data Protection Regulation (GDPR) that went into place May 25. The GDPR seeks to improve the transparency of data usage and give end users more control over their own data. We believe these changes are important and will be compliant with the GDPR regulations.
Contact NAVBO if you have any questions or to
change your communication preferences.
Please note, you can unsubscribe to this newsletter at anytime by clicking on the SafeUnsubscribe in the footer.
|
|
 |
|
Abstract Submission Site Now Open!
Submit your abstract to the Lymphatic Forum 2019, a meeting hosted by Texas A&M University and the Texas Lymphatic Consortium and co-sponsored by NAVBO and the Lymphatic Education & Research Network (LE&RN). The meeting organizers are David Zawieja of TAMU, Stanley Rockson from Stanford University and Jan Kitajewski, University of Illinois at Chicago.
The abstract submission deadline is March 15, 2019
|
Don't Miss These Upcoming Webinars:
February 7 - Stefania Nicoli, Yale University
March 14 - Stryder Meadows, Tulane University
April 11 - William Sessa, Yale University
May 2 - Joyce Bischoff, Boston Children's Hospital
June 13 - Daniel Greif, Yale University
July 11 - Kishore Wary, University of Illinois at Chicago
And don't forget you can watch archived webinars as well - go to
|
Research advocates highlight pathways out of federal shutdown
As the federal government shutdown approached a month in duration, Mary Woolley, President and CEO of the medical research advocacy organization Research!America, penned a morale-boosting letter to all in her network. In addition to reminders of the financial hardships being visited upon furloughed workers, suspensions of research support by NSF and slowed drug approvals at the FDA, Woolley accentuates the positive, drawing attention to ongoing efforts, inside and outside of government, to constructively and cooperatively address the issues that stalled FY19 appropriations bills and forced a partial shutdown.
|
|
Celebrating 25 Years! We want to hear from you!
|
Then and Now!
Where were you in 1994? Had you even thought about the world of vascular biology yet? Let us see the transformation! We want to share images from 1994 and compare them to those from 2019.
Members - share personal photos. Maybe you were a kid in a science fair in 1994 and now you're running your own lab! Or a graduate student and now you're the head of a department.
Technology - if you have images from your 1994 studies, show us how technology has improved to allow you to see vessels, tissue and cells with a whole new perspective.
Scope - what were you working on in 1994? How has your studies and focus evolved? Share some of your discoveries that were a turning point for you and possibly for the field of vascular biology. These stories can be shared in a podcast or short video.
Videos welcomed and encouraged!
We'll create a slide show for the web site and for the
2019 meeting in Monterey!
|
|
Getting to Know More NAVBO Members
|
Meet Ajit Muley
Ajit is a postdoctoral fellow in the Ob-Gyn Department at Columbia University Medical Center. He presented his work,
MMP14 regulates ERK signaling in lymphatic endothelial cells to suppress proliferation in lymphatic valve development and lymphatic malformations, in the Lymphangiogenesis session at Vascular Biology 2018. He received a Travel Award in the Signaling Workshop
(pictured here with workshop co-organizers: Ondine Cleaver and William Sessa).
Ajit recently spoke with Membership Committee Member, Mabruka Alfaidi of LSU Health Sciences Center.
How did you first learn about NAVBO?
The first time I learned about NAVBO was during my PhD training in India in 2006, when my mentor, professor Suvro Chatterjee, recommended that I attend International meetings. NAVBO was one of the best conferences to go to in the Vascular Biology field. I have become a regular member since then.
Tell us about the research you presented and your mentor? My mentor is Dr. Carrie Shawber, she is an expert in NOTCH signaling in lymphatic vessels. When I joined the lab, we wanted to understand the molecular mechanism of the metalloprotease MMP14 in lymphatic vessel pathophysiology. We found that MMP14 regulates Lymphatic endothelial cell proliferation during the development of the lymphatic system. When we looked further into this unique phenomenon, we found that MMP14 regulates the activation of ERK signaling in vitro and in vivo to control cell proliferation. Furthermore, patients suffering from hyperplastic lymphatic malformation lost MMP14 expression from their lymphatic vessels, suggesting loss of LEC MMP14 expression may contribute to the pathological increase in proliferation observed in lymphatic malformations. Our on-going works in this area bring to light a key regulator of the Lymphatic malformation pathology and aims to identify novel therapeutic modality for this disease.
What was your favorite event at the meeting?
The Lymphangiogensis session by far was my best favorite. I learnt a lot and was able to interact and received feedbacks.
Did you meet any people at the meeting who influence your research?
There were quite a few people I was looking forward to meeting and luckily NAVBO vascular biology meeting 2018 was very helpful for me. I met Dr. Sathish Srinivasan and Prof. Holger Gerhardt and was able to discuss common research interests at length. There were many other scientists from across the globe that I met during the conference as well.
What benefits did the travel award have for you?
It helped me by covering part of the travel expense to NAVBO and helped me in attending NAVBO with my lab members.
What benefits can a trainee expect from attending NAVBO?
Research experience is definitely great at NAVBO. I personally gained a lot from NAVBO. I shared my data, hypothesis and got the prospect of how to plan and design critical experiments. Moreover, the one to one interaction between scientists for collaborations and networking is very helpful in building long lasting partnerships.
What future goals do you have for your work? My goal for the current research project is to extend the understanding of MMP14 and its role in lymphatic development. The current work is a part of my mission to identify precision diagnostic and therapeutic targets for lymphatic pathologies and design tailored therapeutic modalities for the patients.
How can NAVBO help you achieve these goals? NAVBO meetings provide a platform for vascular biologists from different focus areas to come together and collaborate freely. Scientists and scholars get to enhance discussion and promote collaboration. This creates a platform to experience different perspectives including vascular biology, genetics and signaling.
|
Meet Nadiya Khyzha
Nadia is a Graduate Student in the University Health Network at the University of Toronto. Nadiya presented a poster entitled,
Regulation of CCL2 expression in vascular endothelial cells by a divergently transcribed long noncoding RNA, in the Signaling workshop at Vascular Biology 2018.
Nadiya recently spoke with Membership Committee member, Mary Wallingford of Tufts University.
How did you first learn about NAVBO? From my lab. Our lab is heavily focused on vascular endothelial cell biology so attending NAVBO is almost a yearly tradition. There's typically at least one person from the lab attending every year.
Tell us about the research you presented? My research looks at the regulation of NF-kB signalling via non-coding mechanisms in endothelial cells. The project that I've presented focused on the role of long non-coding RNAs in acute inflammation and seeing how they fine tune the expression of their neighboring protein coding genes.
How did your mentor facilitate this work? Working on long non-coding RNAs was something completely new in my mentor's lab and in Toronto in general. So, my mentor was very open minded and supportive to try a new avenue of research. I was also given a lot of freedom to play around with different ideas and to establish techniques not previously available in the lab. Perhaps it meant that the project took longer to complete but that was critical for my development as a scientist.
What was your favorite event at the meeting? I'd say the poster sessions and other networking events. It's always nice to meet people and learn about research that's outside the scope of what I'm normally thinking about.
Did you meet any people at the meeting who influence your research? For sure! My research tends to be very molecular based, so it's easy to get caught up in my own niche and lose perspective of the big picture. I find that a lot of the talks at NAVBO take me out of my lncRNA bubble and make me think about how my research applies to vascular biology in the grand scheme of things.
What benefits did the travel award have for you?
Being able to present my work to a wide group of audience has been a really great way to gain exposure for my project. Also, the 2018 meeting had a few researchers working on noncoding RNAs so it was great to get their opinion on my project.
What benefits can a trainee expect from attending NAVBO?
Attending NAVBO is a great opportunity to present your work and get valuable feedback on it. The size of the NAVBO meeting is also perfect to meet people and to form collaborations.
What future goals do you have for your work? Getting it published!
How can NAVBO help you achieve these goals? The lack of community of lncRNA researches in Toronto has been one of the big challenges during my PhD. So, international events like NAVBO are always exciting because it's an opportunity to meet other researchers working on lncRNAs. Now that I'm trying to wrap up my paper, NAVBO has provided me a great opportunity to get that last-minute feedback on my work from other lncRNA researchers.
|
|
Lessons Learned
(from the January 10 issue)
|
Dr. Yun Fang
I started my independent research program in the Department of Medicine, Biological Sciences Division, at The University of Chicago in November 2012. Looking back, it is one of the most challenging, intriguing, and rewarding tasks I have ever undertaken and I would like to use this exciting opportunity to share a few lessons I learned in the past few years.
Be creative, not competitive.
"Be creative but not competitive" is our motto of the lab. It is quite exciting (I feel) to live in the golden age of biomedical research since there are unprecedented advancements of new approaches and techniques which allow us to pursue questions previously unanswerable and to develop new therapies applying these new concepts. One thing I often share with my lab members is that most of the techniques routinely used in my lab nowadays such as ATAC-seq, Hi-C, CRISPR/Cas9-based gene editing, and single-cell sequencing, were not even invented when I was a postdoctoral fellow. Finding creative ways to identify new questions and novel solutions are always recommended and encouraged in my lab. Nevertheless, it is important to maintain a fine balance between being creative and focused for a junior faculty member who not only needs to move the chosen field forward but also show continuous research productivity.
Read more on the NAVBO website about Dr. Fang's thoughts on collegiality, finding collaborators, and communicating your passion.
|
|
Lab of the Month
(from the January 10 issue)
|
|
Spotlight on Trainees
(from the January 10 issue)
|
Quality mentoring of PhD scientists crucial for success in career launch
Andrea M. Zimmerman from the Office of Continuing Medical Education at the University of Virginia has published "Navigating the path to a biomedical science career" in PLoS One (9/7/18), examining the multifactorial nature of PhD trainees' experiences in the biomedical sciences and how they approach their career choices. It is well known that the number of newly-minted life science PhDs exceeds the number of opportunities in academe. Using social cognitive career theory and data gleaned from case studies, the author concludes that mentoring relationships with faculty are key to successful navigation of career paths in a challenging employment marketplace.
|
Welcome to our New Members:
Hyunwoo Choi, Dignity Health/ Barrow Neurological Institute
Rosamaria Correra, UCL Institute of Ophthalmology
Bhupesh Singla, Augusta University
|
|
Recent Publications by NAVBO Members
|
| Spatially controlled assembly of affinity ligand and enzyme cargo enables targeting ferritin nanocarriers to caveolae
Biomaterials
One of the goals of nanomedicine is targeted delivery of therapeutic enzymes to the sub-cellular compartments where their action is needed. Endothelial caveolae-derived endosomes represent an important yet challenging destination for targeting, in part due to smaller size of the entry aperture of caveolae (ca. 30-50nm). Read more Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner
Journal of Cellular and Molecular Medicine
Endothelial diaphragms are subcellular structures critical for mammalian survival with poorly understood biogenesis. Plasmalemma vesicle associated protein (PLVAP) is the only known diaphragm component and is necessary for diaphragm formation. Read more Loss of estrogen-related receptor alpha facilitates angiogenesis in endothelial cells
Molecular and Cellular Biology
Estrogen-related receptors (ERRs) have emerged as major metabolic regulators in various tissues. However, their expression and function in the vasculature remains unknown. Read more Cardiovascular protection in females linked to estrogen-dependent inhibition of arterial stiffening and macrophage MMP12
Journal of Clinical Investigation Insight
Arterial stiffening is a consequence of aging and a cholesterol-independent risk factor for cardiovascular disease (CVD). Arterial stiffening and CVD show a sex bias, with men more susceptible than premenopausal women. Read more Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation
Arteriosclerosis, Thrombosis, and Vascular Biology
Objective- Venous malformations (VMs) arise from developmental defects of the vasculature and are characterized by massively enlarged and tortuous venous channels. Read more |
Industry News (from the January 10 issue)
|
|
"Million Hearts 2022" seeks to reduce mortality in cardiovascular disease
The profound advances in prevention, diagnosis and treatment of heart and peripheral vascular diseases over the last half century resulted in a celebrated drop in rates of death owing to cardiovascular disorders. Now, this drop has abated and even changed course in adults aged 35 to 64, where deaths attributable to heart disease are on the increase. In view of this shift in medical fortunes, the US Centers for Disease Control and Prevention has launched Million Hearts 2022, emphasizing adoption of, and adherence to, those measures already proven to improve and sustain cardiovascular health. Janet Wright, MD, and her CDC colleagues
note in JAMA that persistence of multiple behaviors and other factors stand in the way of progress, notably physical inactivity, smoking, uncontrolled high blood pressure, and hypercholesterolemia.
What makes science 'hard' in an era when the very value and nature of evidence is questioned?
French philosopher Bruno Latour created a stir in the late 20th century by positing that scientific facts were "social constructions," that is, created by scientific research rather than standing freely and objectively apart from the investigation that reveals said facts. The "realists" who countered this view feared that constructionists would undermine scientific progress, legitimizing creationism and encouraging the anti-vaccine movement. The debate produced memorable salvos, including an invitation from physicist Alan Sokal that Latour step out his 21st-floor window if the laws of physics were nothing more than social conventions. In the New York Times Magazine, Ava Kofman explores the implications of Latour's legacy for the present post-fact era.
Cardiovascular aspects of endocrine disorders highlighted
The Endocrine Society has joined forces with the medical information system MedPage Today and the American College of Cardiology (ACC) to create an online resource that brings to the foreground leading research exploring important connections between cardiovascular and endocrine diseases. Dubbed the Cardio-Endo Connection, the web presence aims to inform both primary care physicians and endocrine and CV specialists about important mutual concerns. The site's inaugural offerings probe cardiovascular benefits of modified metformin therapy in Type 2 diabetes as well as management of primary aldosteronism.
|
|
|
